

GENOME THERAPEUTICS CORP

Form 8-K

October 04, 2001

-----  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 8-K

CURRENT REPORT  
Pursuant to

Section 13 or 15(d) of

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): October 4, 2001

-----  
GENOME THERAPEUTICS CORP.  
(Exact name of registrant as specified in its charter)

MASSACHUSETTS

0-10824

04-2297484

(State or other jurisdiction  
of incorporation)

(Commission File Number)

(I.R.S. Employer  
Identification Number)

100 BEAVER STREET  
WALTHAM, MASSACHUSETTS 02453

(Address, of principal executive offices, including zip code)

(781) 398-2300

(Registrant's Telephone number including area code)

-----  
PAGE 1 OF 3 PAGES.

Edgar Filing: GENOME THERAPEUTICS CORP - Form 8-K

Item 5. OTHER EVENTS

Due to current market conditions, Genome Therapeutics Corp. has decided to discontinue its offer and sale of up to 1,950,000 shares of common stock (the "Shares") as described in the prospectus supplement dated June 28, 2001, filed with the Securities and Exchange Commission pursuant to Rule 424(b)(5) of the Securities Act of 1933, as amended. The Company intends to continue to evaluate market conditions and may seek to sell the Shares through underwriters, dealers or agents or directly to one or more purchasers.

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENOME THERAPEUTICS CORP.

By /s/ Stephen Cohen

-----

Name: Stephen Cohen

Title: Chief Financial Officer

Date: October 4, 2001

